Copyright
©The Author(s) 2025.
World J Virol. Dec 25, 2025; 14(4): 115626
Published online Dec 25, 2025. doi: 10.5501/wjv.v14.i4.115626
Published online Dec 25, 2025. doi: 10.5501/wjv.v14.i4.115626
Table 1 Comparison between patients requiring antiviral therapy and those with spontaneous clearance, median (interquartile ranges)
| Variable | Treated (n = 6) | Not treated (n = 11) | P value (Mann-Whitney U/Fisher exact) |
| Age (years) | 45 (33, 61) | 39 (23, 60) | 0.309 |
| Sex (male/female) | 4/2 | 6/5 | 0.205 |
| Initial VL (IU/mL) | 1631 (612, 50200) | 690 (150, 1990) | 0.015 |
| Peak VL (IU/mL) | 30150 (812, 641000) | 1320 (150, 18000) | 0.007 |
| Time to reactivation (days) | 24 (9, 29) | 25 (5, 38) | 0.66 |
| Time to neutrophil engraftment (days) | 11 (10, 12) | 12 (10, 19) | 0.884 |
- Citation: Ben Moussa ML, Chelbi Y, Kharrat R, Berred R, Ben Lakhal R, Hamdoun M, Bahri O. Cytomegalovirus reactivation risk after autologous hematopoietic stem cell transplantation: Results of a Tunisian study. World J Virol 2025; 14(4): 115626
- URL: https://www.wjgnet.com/2220-3249/full/v14/i4/115626.htm
- DOI: https://dx.doi.org/10.5501/wjv.v14.i4.115626
